- Pressemitteilung BoxID 544800
4SC strengthens patent protection for lead cancer compound resminostat
US patent for medical use in cancer and Canadian composition of matter patent granted
For the epigenetic agent resminostat, an HADC inhibitor targeting in particular HDAC 1, 2, 3 and 6, the US Patent Office has granted the patent for the medical use in cancer indications. The patent relates to the so-called method of treatment claims, and covers medical application of resminostat in mono- and/or combination therapy for cancer indications.
In addition, the Canadian patent authority has granted the composition of matter patent for resminostat. Thus resminostat has now composition of matter protection in all major markets including the US, Europe, Japan, China, South Korea, Russia, India, and now Canada.
The granting of the two patents constitutes an additional protection against potential competitors and thus further strengthens the protection of 4SC's intellectual property assets, including the composition of matter, mesylate salt and manufacturing patents of resminostat, for which up to date patents have been granted in 58 countries, including the major markets.
Enno Spillner, Chief Executive Officer of 4SC, said: "We are pleased to announce the recent additions to our patent portfolio. The two patents will further strengthen not only the wide strategic position of our resminostat programme but also of 4SC as an important player in the field of epigenetic cancer therapies." Enno Spillner continued: "Especially, the resminostat medical application patent shows the broad possibilities of future use of our lead drug candidate. This is in particular evident in the light of the recently announced additional clinical use by our partner Yakult Honsha in pancreatic and biliary tract cancer as well as our own planned European Phase II trial in the indication of CTCL."
Resminostat (4SC-201) is an oral histone-deacetylase (HDAC) inhibitor, targeting in particular HDAC 1, 2, 3 and 6, with an innovative epigenetic mechanism of action that potentially enables the compound to be deployed as a novel, targeted tumour therapy for a broad spectrum of oncological indications, both in monotherapy and, in particular, in combination with other cancer drugs. Like other epigenetic therapies, resminostat modifies transcription of genes in cancer cells and, thereby, reprograms the phenotypes of such cancer cells. Additionally, resminostat has immunotherapeutic effects by activating NK cells, restoring MHCI and MHCII proteins and suppression of unspecific immunosuppression. Resminostat is assumed to be able to halt tumour progression and induce tumour regression. Furthermore, due to its epigenetic mode of action resminostat is supposed to develop additional synergetic effects when combined with classical cancer therapies and to counteract the development of tumour cell resistance.
Resminostat - by 4SC and its Japanese partner Yakult - has been investigated or is currently being investigated in a broad clinical campaign comprising liver cancer (HCC), Hodgkin's Lymphoma (HL), colorectal cancer (CRC), non-small-cell lung cancer (NSCLC), pancreatic and biliary tract cancer. Resminostat is partnered with Yakult Honsha for Japan and with Menarini AP in the Asia Pacific (APAC) region excluding Japan. 4SC is currently in preparations of a randomised, controlled Phase II trial in the indication of advanced cutaneous T-cell lymphoma (CTCL) in Europe.
Cautionary statement regarding forward-looking statements
This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and 4SC AG has no obligation to update any such information or to correct any inaccuracies herein or omission herefrom which may become apparent.
For more information please visit www.4sc.com
The Group managed by 4SC AG (ISIN DE000A14KL72) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount of 68 employees (58 FTEs) at 31 March 2015. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.
Diese Pressemitteilungen könnten Sie auch interessieren
Weit mehr als 8.000 Verantwortungsträger aus dem deutschen Gesundheitswesen sind in diesem Jahr beim Hauptstadtkongress Medizin & Gesundheit...
Aktion rund um Weltblutspendertag erfolgreich #missingtype lässt „O“ für eine Woche aus dem Logo verschwinden Rund um den Weltblutspendertag...